Key result
GDMT prompts heart failure recovery in late-onset doxorubicin-induced cardiotoxicity.
Why the study?
Anthracyclines such as doxorubicin increase the risk of heart failure with significant morbidity and mortality, but late onset doxorubicin-induced heart failure remains a diagnostic challenge.
Case Report (n=1)
This case highlights the occurrence of late-onset doxorubicin-induced cardiomyopathy and its potential for recovery with standard heart failure therapy.
Answers are grounded in this paper and cite their sources.
May support GDMT use in late-onset doxorubicin cardiomyopathy; hypothesis-generating and should not yet change practice.
Heart failure (HF) is a clinical syndrome with a wide spectrum of presentations and an even wider array of etiologies. Anthracyclines such as Doxorubicin, Daunorubicin, Idarubicin, and Epirubicin have demonstrated increased risk of HF with significant morbidity and mortality. We present an interesting case report of a patient with a history of breast cancer treated with Doxorubicin who presented with symptoms of HF who had a comprehensive evaluation that excluded the most common etiologies, narrowing our diagnosis to late onset doxorubicin induced HF with on-going recovery after initiation of guideline-directed medical therapy.
No takes yet. Share an insight, caveat, or question.
Song et al. (2023) conducted a case report in Heart failure and breast cancer (n=1). Doxorubicin was evaluated on Late onset doxorubicin induced heart failure. A patient treated with Doxorubicin for breast cancer developed late-onset heart failure, which showed ongoing recovery after initiation of guideline-directed medical therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: